Travere Therapeutics NASDAQ: TVTX reported third-quarter results marked by record FILSPARI sales, continued early adoption in focal segmental glomerulosclerosis (FSGS), and progress across its kidney-disease and rare-disease pipeline.Total U.S. net product sales reached $220.2 million in the third quarter, led by $200.2 million in FILSPARI sales. FILSPARI sales increased approximately 120% from a year earlier, reflecting continued growth in immunoglobulin A nephropathy (IgAN) and the first significant reven ...

Travere Therapeutics (NasdaqGM:TVTX) Q3 2026 Earnings call November 02, 2026 04:30 PM ET Company ParticipantsEric Dube - President and CEOPeter Heerma - Chief Commercial OfficerJula Inrig - Head of R&D and Chief Medical OfficerChris Cline - CFOLaura Chico - Managing Director, Co-Head of Healthcare ResearchJoe Schwartz - Managing DirectorGavin Clark-Gartner - Managing DirectorPrakhar Agrawal - Managing DirectorSadia Rahman - Vice PresidentAlex Thompson - Research Managing DirectorVamil Divan - Managing Direc ...

Travere Therapeutics (NasdaqGM:TVTX) Q3 2026 Earnings call November 02, 2026 04:30 PM ET Speaker0Good afternoon, and welcome to the Travere Therapeutics Third Quarter 2026 Financial Results Conference Call. Today's call is being recorded. At this time, I would like to turn the conference call over to Ryan Hayes, Investor Relations Analyst. Please go ahead, Ryan.Speaker1Thank you, operator. Good afternoon, and welcome to Travere Therapeutics' Third Quarter 2026 Financial Results and Corporate Update Call. Th ...